ProCE Banner Activity

Phase I/Ib Study of Mosunetuzumab in Heavily Pretreated Patients With R/R B-Cell Non-Hodgkin Lymphoma

Slideset Download
Conference Coverage
CRs observed with single-agent mosunetuzumab, a bispecific antibody, in patients with R/R B-cell NHL, including patients with aggressive disease.

Released: December 12, 2019

Expiration: December 10, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company